1-12 of 12
Sher Karki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Nandini Rudra-Ganguly, PhD, Christine Lowe, Cyrus Virata, Monica Leavitt, Liqing Jin, MD, Brian Mendelsohn, PhD, Josh Snyder, Hector Aviña, Chunying Zhang, Deanna L Russell, Michael Mattie, PhD, Peng Yang, PhD, Baljinder Randhawa, Gao Liu, Faisal Malik, Misty Vest, Joseph D Abad, Christopher C Kemball, PhD, René Hubert, PhD, Sher Karki, PhD, Banmeet Anand, PhD, Zili An, MD, Jeanette Grant, PhD, John E. Dick, PhD, Fernando Doñate, PhD, Kendall Morrison, PhD, Pia Challita-Eid, PhD, Ingrid B Joseph, DVM, PhD, Daniel S. Pereira, PhD, David R. Stover, PhD
Journal: Blood
Blood (2015) 126 (23): 3806.
https://doi.org/10.1182/blood.V126.23.3806.3806
Published: 2015
Journal Articles

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

Yu-Tzu Tai, Holly M. Horton, Sun-Young Kong, Erik Pong, Hsing Chen, Saso Cemerski, Matthew J. Bernett, Duc-Hanh T. Nguyen, Sher Karki, Seung Y. Chu, Greg A. Lazar, Nikhil C. Munshi, John R. Desjarlais, Kenneth C. Anderson, Umesh S. Muchhal
Journal: Blood
Blood (2012) 119 (9): 2074–2082.
https://doi.org/10.1182/blood-2011-06-364521
Published: 2012
Includes: Supplemental data
Journal Articles

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

Holly M. Horton, Matthew J. Bernett, Matthias Peipp, Erik Pong, Sher Karki, Seung Y. Chu, John O. Richards, Hsing Chen, Roland Repp, John R. Desjarlais, Eugene A. Zhukovsky
Journal: Blood
Blood (2010) 116 (16): 3004–3012.
https://doi.org/10.1182/blood-2010-01-265280
Published: 2010
Journal Articles

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Umesh Muchhal, Ph.D., Xian-Feng Li, MS, Sabikun Nahar, B.S., Weihua Song, MD, Holly Horton, Ph.D, Hanh Nguyen, Sher Karki, John Desjarlais, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 609.
https://doi.org/10.1182/blood.V114.22.609.609
Published: 2009
Journal Articles

The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates

Jonathan Zalevsky, Irene W. L. Leung, Sher Karki, Seung Y. Chu, Eugene A. Zhukovsky, John R. Desjarlais, David F. Carmichael, Chris E. Lawrence
Journal: Blood
Blood (2009) 113 (16): 3735–3743.
https://doi.org/10.1182/blood-2008-10-182048
Published: 2009
Journal Articles

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Eugene A. Zhukovsky, PhD, Holly Horton, Ph.D, Matthias Peipp, PhD, Erik Pong, BS, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Seung Chu, PhD, Roland Repp, MD, John Desjarlais, PhD
Journal: Blood
Blood (2008) 112 (11): 881.
https://doi.org/10.1182/blood.V112.11.881.881
Published: 2008
Journal Articles

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Chris E Lawrence, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Irene Leung, PhD, Seung Chu, PhD, Sher Karki, PhD, Eugene Zhukovsky, PhD, John R Desjarlais, PhD, David F Carmichael, PhD
Journal: Blood
Blood (2008) 112 (11): 2621.
https://doi.org/10.1182/blood.V112.11.2621.2621
Published: 2008
Journal Articles

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Eugene Zhukovsky, PhD, Seung Chu, PhD, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Erik Pong, BS, Matthias Peipp, PhD, Roland Repp, MD, John Desjarlais, PhD
Journal: Blood
Blood (2007) 110 (11): 2335.
https://doi.org/10.1182/blood.V110.11.2335.2335
Published: 2007
Journal Articles

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Chris E. Lawrence, PhD, Phil W. Hammond, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Seung Chu, PhD, Sher Karki, PhD, John R. Desjarlais, PhD, David F. Carmichael, PhD
Journal: Blood
Blood (2007) 110 (11): 2340.
https://doi.org/10.1182/blood.V110.11.2340.2340
Published: 2007
Journal Articles

Fc Engineered Anti-CD19 Monoclonal Antibodies with Enhanced In Vitro Efficacy Against Multiple Lymphoma Cell Lines.

Eugene A. Zhukovsky, PhD, Seung Chu, Ph.D., Matthew Bernett, Ph.D., Philip Hammond, Ph.D., Sher Karki, Ph.D., Wei Dang, Ph.D., Collin Edler, M.S., Nephi Polder, B.S., Cheryl Chan, B.S., Jonathan Jacinto, B.S., John Desjarlais, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 4747.
https://doi.org/10.1182/blood.V108.11.4747.4747
Published: 2006
Journal Articles

A Humanized Anti-CD30 Monoclonal Antibody, XmAb ™ 2513, with Enhanced In Vitro Potency Against CD30-Positive Lymphomas Mediated by High Affinity Fc-Receptor Binding.

Philip W. Hammond, Omid Vafa, Jonathan Jacinto, Jost Vielmetter, Sher Karki, Sean Yoder, Greg Lazar, Dinesh Raturi, Mike Mollet, Marie Zhu, Lori Kunkel, David Carmichael
Journal: Blood
Blood (2005) 106 (11): 1470.
https://doi.org/10.1182/blood.V106.11.1470.1470
Published: 2005
Journal Articles

Improving the Efficacy of Rituxan by Rational Protein Engineering.

Greg Lazar, PhD, Wei Dang, PhD, Omid Vafa, PhD, Sher Karki, PhD, Jost Vielmetter, PhD, Stephen Doberstein, PhD, David Carmichael, PhD, Robert Hayes, PhD
Journal: Blood
Blood (2004) 104 (11): 1405.
https://doi.org/10.1182/blood.V104.11.1405.1405
Published: 2004